KZRHIGH SIGNALRISK10-K

Kezar Life Sciences is winding down operations and exploring strategic alternatives after failing to align with the FDA on their lead drug candidate's clinical development path.

The company has essentially abandoned its core business model of developing immunoproteasome inhibitors after unsuccessful FDA negotiations regarding zetomipzomib's registrational trial for autoimmune hepatitis. While they received a new FDA meeting in January 2026, the implementation of restructuring and wind-down plans suggests management has lost confidence in the viability of their development program as an independent entity.

Comparing 2026-03-27 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

The financial picture reflects a company in wind-down mode, with total assets declining 47% to $76.6M and stockholders' equity falling 40% to $70.1M, while paradoxically cash increased 72% to $71.9M likely from asset liquidation and cost reduction efforts. Operating losses improved 35% as R&D spending was slashed nearly in half from $65.7M to $33.8M, and total liabilities dropped 76% to $6.6M, indicating aggressive cost-cutting and settlement of obligations. This combination of rising cash, declining assets, and reduced burn rate is consistent with a controlled wind-down rather than ongoing business operations.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
-76.3%
$27.8M→$6.6M

Liabilities reduced 76.3% — deleveraging improves balance sheet strength and financial flexibility.

Capital Expenditure
Cash Flow
-72.4%
$29K→$8K

Capex reduced 72.4% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+72.2%
$41.7M→$71.9M

Cash position surged 72.2% — strong cash generation or capital raise providing significant financial cushion.

Current Liabilities
Balance Sheet
-67.7%
$20.3M→$6.6M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
-48.7%
$65.7M→$33.8M

R&D spending cut 48.7% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
-47%
$144.7M→$76.6M

Total assets contracted 47% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-44.9%
$137.5M→$75.7M

Current assets declined 44.9% — monitor working capital adequacy and short-term liquidity.

Stockholders Equity
Balance Sheet
-40.1%
$116.9M→$70.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Income
P&L
+34.8%
-$90.6M→-$59.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Net Income
P&L
+33.1%
-$83.7M→-$56.0M

Net income grew 33.1% — bottom-line growth signals improving overall business health.

LANGUAGE CHANGES
NEW — 2026-03-27
PRIOR — 2025-03-25
ADDED
The Proxy Statement or an Annual Report on Form 10-K/A will be filed with the Securities and Exchange Commission within 120 days of the registrant s fiscal year ended December 31, 2025.
Kezar Life Sciences Australia Pty Ltd., which was legally dissolved as of September 29, 2025, was a private limited company, registered in Australia.
In October 2025, we announced plans to explore strategic alternatives focused on maximizing stockholder value after being unable to align with the U.S.
Food and Drug Administration, or FDA, on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome in patients with relapsed and refractory autoimmune hepatitis, or AIH.
Following this announcement, we have been implementing a restructuring plan and wind-down of our business operations to focus on strategic alternatives for zetomipzomib development.
In January 2026, we announced that the FDA Division of Hepatology and Nutrition granted us a new Type C meeting to discuss the development of zetomipzomib in patients with AIH.
This Type C meeting would involve a review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory AIH.
As part of the briefing package submitted to the FDA, Kezar submitted pharmacokinetic and hepatic safety data analyses from previously conducted clinical trials to support a proposal for parallel AIH and hepatic impairment studies.
Kezar also submitted additional safety data and an updated risk-mitigation plan aimed to modify the previous requirement issued from the FDA to require 48-hour in-unit patient monitoring in future AIH studies.
In March 2026, we completed a successful Type C with the FDA during which the FDA provided constructive feedback and critical guidance on the regulatory pathway for development of zetomipzomib in AIH, including agreement with us on treatment duration, endpoints and enrollment criteria.
REMOVED
The Proxy Statement will be filed with the Securities and Exchange Commission within 120 days of the registrant s fiscal year ended December 31, 2024.
We believe therapies that inhibit multiple drivers of disease by targeting fundamental upstream control processes within the cell have the potential for profound therapeutic benefit in a number of difficult-to-treat diseases.
To that end, we are advancing a drug development program that harnesses a key regulator of cellular function by targeting the immunoproteasome, which is responsible for protein degradation in cells of the immune system and drives many key aspects of immune cell function.
We believe targeting this fundamental regulator of cellular function offers an attractive approach to treating autoimmune diseases.
Our product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that we are evaluating for the treatment of severe autoimmune diseases of high unmet medical need.
Clinical Development of Zetomipzomib We are focusing the development of zetomipzomib in autoimmune hepatitis, or AIH, a rare, chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients health and quality of life.
In accordance with the AASLD treatment guidelines, and supported by our PORTOLA results described below, we expect to design our next AIH clinical trial to have an efficacy endpoint of patients achieving a CR with a successful steroid taper.
Following the completion of the MISSION trial, we initiated the PALIZADE trial, which compared the safety and efficacy of two dose levels of zetomipzomib to placebo in patients with active, proliferative LN who were receiving standard of care therapy, namely high dose prednisone and mycophenylate mofetil (CellCept ).
Food and Drug Administration, or FDA, Division of Rheumatology and Transplant Medicine following recommendation from the independent safety monitoring committee, based on review of 15 serious adverse events, or SAEs, including four fatalities: one in the placebo arm, two in the 30 mg zetomipzomib arm, and one in the 60 mg zetomipzomib arm.
In October 2024, following the clinical hold on PALIZADE, the FDA notified us that patients enrolled in PORTOLA could complete the double-blind treatment period, or DBTP, without modification.
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →